Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$12.87M+2419.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pravin U. Dugel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 325
- Beta
- 0.99
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.07
Financials
Revenue
$12.87M+2419.4%Net Income
$-94.78MEBITDA
$-89.54MFree Cash Flow
$-68.65MEPS (diluted)
$-0.42Shares Outstanding (diluted)
225.52M+806.1%Operating Expenses
$109.28MCash & Debt
$530.61MReturn of Capital
$0.00Revenue by Segment (annual)
$51.95MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $51.82M | $-265.94M | $-1.42 |
| 2024 | $63.72M | $-193.51M | $-1.22 |
| 2023 | $58.44M | $-80.74M | $-1.09 |
| 2022 | $51.49M | $-71.04M | $-1.04 |
| 2021 | $43.52M | $-6.55M | $-1.05 |
| 2020 | $17.40M | $-155.64M | $-2.56 |
| 2019 | $4.23M | $-86.37M | $-1.91 |
| 2018 | $1.99M | $-57.69M | $-1.57 |
| 2017 | $1.92M | $-63.39M | $-2.20 |
| 2016 | $1.89M | $-44.70M | $-1.80 |
| 2015 | $1.75M | $-39.75M | $-1.71 |
| 2014 | $772.0K | $-28.65M | $-2.69 |
| 2013 | $0.00 | $-13.32M | $-4.52 |
| 2012 | $10.0K | $-14.09M | $-4.78 |
Valuation
OCULhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (11)
- Newsmarketbeat.com·8h ago·Neutral
Ocular Therapeutix Targets Q4 FDA Filing for AXPAXLI After Key Trial Win Ocular Therapeutix NASDAQ: OCUL remains on track to submit a U.S. marketing application this quarter for AXPAXLI, its experimental treatment for wet age-related macular degeneration, CEO Pravin Dugel said at the UBS Global Biopharma Conference in London.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·13d ago·Neutral
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call Ocular Therapeutix NASDAQ: OCUL plans to submit a U.S. application in the fourth quarter of 2026 for AXPAXLI, its investigational treatment for wet age-related macular degeneration, executives said on the company's third-quarter earnings call.
View source ↗ - Newsglobenewswire.com·20d ago·Negative
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026 BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·24d ago·Negative
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.
View source ↗ - Newsseekingalpha.com·28d ago·Neutral
Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity Ocular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expected in Q4 and potential 2027 launch. The market is pricing in $1.26 billion in peak U.S. sales for OCUL after competitor advances, lost takeover premium, and rising cash burn.
View source ↗ - Newsseekingalpha.com·30d ago·Positive
Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript
View source ↗ - Newsglobenewswire.com·52d ago·Negative
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.
View source ↗ - Newsglobenewswire.com·82d ago·Negative
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.
View source ↗ - Newsseekingalpha.com·96d ago·Positive
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
View source ↗ - Newsbenzinga.com·97d ago·Neutral
Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $-0.45 per share
Typical surprise -11.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.42 vs $-0.36miss
- Mon, Aug 3$-0.35 vs $-0.40beat
- Tue, May 5$-0.41 vs $-0.32miss
- Thu, Feb 5$-0.29 vs $-0.33beat
- Tue, Nov 4$-0.37 vs $-0.39beat
- Tue, Aug 5$-0.39 vs $-0.35miss
Estimates and results for OCUL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OCUL officers and directors.
- Bought
- $461k
- Sold
- $4.3m
1 trade
38 trades
- Saroj Namratasold
- Anderman Toddsold
- Kaiser Petersold
- Heier Jeffrey S.sold
- Notman Donaldsold
- Kaiser Petersold
- Nayak Sanjaysold
- Heier Jeffrey S.sold
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OCUL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
